Super Micro Computer Reports Disappointing Q1 Results, Alongside Pinterest, Axon Enterprise, and Other Major Stocks Declining in Wednesday's Pre-Market Trading
Written by Emily J. Thompson, Senior Investment Analyst
Source: Benzinga
Updated: Nov 05 20250mins
U.S. Stock Market Trends: U.S. stock futures are down, with the Dow futures dropping over 50 points, reflecting a negative market sentiment.
Super Micro Computer Performance: Super Micro Computer Inc. shares fell 9.2% after reporting disappointing first-quarter earnings of 35 cents per share, missing estimates, and issuing lower second-quarter EPS guidance.
Other Notable Stock Declines: Several companies, including Biohaven Ltd and Trex Company Inc, experienced significant pre-market declines, with Biohaven tumbling 46.2% after receiving an FDA Complete Response Letter.
Mixed Results from Major Firms: Companies like Axon Enterprise and Pinterest reported mixed third-quarter results, leading to notable drops in their stock prices, with Axon down 19.6% and Pinterest down 18.8%.
BHVN.N
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on BHVN
Wall Street analysts forecast BHVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BHVN is 21.30 USD with a low forecast of 9.00 USD and a high forecast of 54.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
8 Buy
4 Hold
0 Sell
Moderate Buy
Current: 8.300
Low
9.00
Averages
21.30
High
54.00
Current: 8.300
Low
9.00
Averages
21.30
High
54.00
Citi
Buy
downgrade
$28 -> $14
2025-11-13
New
Reason
Citi
Price Target
$28 -> $14
2025-11-13
New
downgrade
Buy
Reason
Citi lowered the firm's price target on Biohaven to $14 from $28 and keeps a Buy rating on the shares. The firm cites the complete response letter in spinocerebellar ataxia for the target cut. Citi remains cautious into Biohaven's upcoming Phase 3 depression data but says the recent equity raise alleviates a near-term financing overhang.
BTIG
Buy
downgrade
$33 -> $16
2025-11-06
Reason
BTIG
Price Target
$33 -> $16
2025-11-06
downgrade
Buy
Reason
BTIG lowered the firm's price target on Biohaven to $16 from $33 and keeps a Buy rating on the shares following Tuesday's announcement of the complete response letter for troriluzole in SCA. The CRL likely "ends a messy chapter" for the company in SCA, the analyst tells investors in a research note. The 60% R&D restructuring is hard to model without details, so the calculated $16 TP may be a little low pending a better read on cuts, the firm added.
Piper Sandler
Piper Sandler
Overweight
downgrade
$75 -> $30
2025-11-06
Reason
Piper Sandler
Piper Sandler
Price Target
$75 -> $30
2025-11-06
downgrade
Overweight
Reason
Piper Sandler lowered the firm's price target on Biohaven to $30 from $75 and keeps an Overweight rating on the shares following the FDA's complete response letter for troriluzole in spinocerebellar ataxia, citing RWE and natural history study issues. This follows a complex regulatory history with an initial RTF letter, followed by NDA acceptance in February based on statistical significance benefits from an FDA-guided RWE protocol. Piper views the FDA's decision as a concerning instance of inconsistent guidance.
Bernstein
Outperform -> Market Perform
downgrade
$34 -> $9
2025-11-06
Reason
Bernstein
Price Target
$34 -> $9
2025-11-06
downgrade
Outperform -> Market Perform
Reason
Bernstein downgraded Biohaven to Market Perform from Outperform with a price target of $9, down from $34, following Tuesday's announcement of the complete response letter for troriluzole in SCA. This is a painful downgrade, the firm notes, as Bernstein remains excited about the long-term value of the degrader platform, the original reason for its Outperform rating.
See All Ratings
About BHVN
Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development and commercialization of treatments in key therapeutic areas, including immunology, neuroscience, and oncology. It is advancing its portfolio of therapeutics, leveraging its drug development experience and multiple proprietary drug development platforms. Its clinical and preclinical programs include Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for immunological diseases; TRPM3 antagonism for migraine and neuropathic pain; TYK2/JAK1 inhibition for neuroinflammatory disorders; glutamate modulation for obsessive-compulsive disorder (OCD) and spinocerebellar ataxia (SCA); myostatin inhibition for neuromuscular and metabolic diseases, including spinal muscular atrophy (SMA) and obesity; antibody recruiting bispecific molecules; and antibody drug conjugates for cancer. Its advanced product candidate from its glutamate receptor antagonist platform is troriluzole.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What are the main purposes of Biohaven's public share offerings?
How does Biohaven plan to utilize the proceeds from its offerings?
How might Biohaven's stock price react to the FDA's decision on Troriluzole?
What impact could Biohaven's cost optimization strategy have on its financial performance?